Investigating DNA repair capacity in blood cells as a risk factor for breast cancer
Homologous recombination repair capacity in peripheral blood lymphocytes as a breast cancer risk factor
This study is looking at how well blood cells can fix DNA damage to see if it can help identify women who might be at a higher risk for breast cancer, so they can get better screening and support.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10909392 on NIH RePORTER |
What this research studies
This research focuses on understanding how the ability of blood cells to repair DNA damage may influence the risk of developing breast cancer. By measuring homologous recombination repair (HRR) capacity in peripheral blood lymphocytes, the study aims to identify women who are at higher risk for breast cancer and may benefit from targeted screening. The approach involves developing a non-invasive assay to assess HRR capacity, which could provide valuable insights into breast cancer susceptibility. Ultimately, this research seeks to improve risk prediction and screening strategies for breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are women who may be at risk for breast cancer, particularly those without a known family history of the disease.
Not a fit: Patients who have already been diagnosed with breast cancer or those with established genetic mutations linked to breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better identification of women at risk for breast cancer, allowing for more personalized and effective screening strategies.
How similar studies have performed: Previous research has shown promise in using DNA repair capacity as a biomarker for cancer risk, suggesting that this approach may yield valuable insights.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Zhao, Hua — University of Virginia
- Study coordinator: Zhao, Hua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.